US asset managers increase stakes in WuXi AppTec amid weight-loss drug demand

Major US asset managers, including BlackRock, have increased holdings in Chinese pharmaceutical contractor WuXi AppTec, anticipating revenue growth from surging global demand for weight-loss drug manufacturing. This investment trend persists despite ongoing geopolitical scrutiny of Chinese biotech firms by US lawmakers. It remains uncertain whether potential legislative restrictions on Chinese contract research organizations will impact these long-term positions.